News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NicOx SA (COX.PA) First Half 2017 Business And Financial Update



9/8/2017 8:23:49 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced its financial results for the six months ended June 30, 2017, and provided an update on its activities.

"The first half of 2017 was marked by significant developments across our core programs" commented Michele Garufi, Chairman and Chief Executive Officer of Nicox. "The recent FDA approval of the ZERVIATE(TM) NDA brings us one step closer to our objective of securing a commercialisation partner for this innovative ophthalmic product for the U.S. market. For VYZULTA(TM), our partner Bausch + Lomb has resolved the FDA's concerns surrounding their Tampa manufacturing plant and rapidly submitted a response to the CRL received in August."

Read at GlobeNewswire


comments powered by Disqus
NicOx SA
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES